112 related articles for article (PubMed ID: 3076200)
21. Bromocriptine and levodopa (with or without carbidopa) in parkinsonism.
Kartzinel R; TEYCHENNE P; Gillespie MM; Perlow M; Gielen AC; Sadowsky DA; Calne DB
Lancet; 1976 Aug; 2(7980):272-5. PubMed ID: 59850
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of parkinson disease with the combination of L-dopa (plus carbidopa) and trazodone].
Piccinin GL; Piccirilli M; Agostini L
Clin Ter; 1981 Mar; 96(6):621-6. PubMed ID: 7285527
[No Abstract] [Full Text] [Related]
23. [The treatment of Parkinson disease using the combination bromocriptine and levodopa].
Dufresne JJ
Rev Med Suisse Romande; 1990 Jun; 110(6):559-64. PubMed ID: 2367793
[No Abstract] [Full Text] [Related]
24. Clinical administration of parlodel in low doses.
Lipcsey A; Peres A
Adv Neurol; 1984; 40():557-61. PubMed ID: 6695636
[No Abstract] [Full Text] [Related]
25. A progress report on the New Zealand Multicentre Parkinson's disease trial. A comparison of low-dose treatment with bromocriptine or L-dopa.
Wallis WE
Eur Neurol; 1988; 28 Suppl 1():9-10. PubMed ID: 3288479
[TBL] [Abstract][Full Text] [Related]
26. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism.
Sage JI; Trooskin S; Sonsalla PK; Heikkila R; Duvoisin RC
Ann Neurol; 1988 Jul; 24(1):87-9. PubMed ID: 3415201
[TBL] [Abstract][Full Text] [Related]
27. Dopaminergic agonists in Parkinsonism.
Claveria LE; Teychenne PF; Calne DB; Petrie A; Bassendine MF
Adv Neurol; 1975; 9():383-92. PubMed ID: 1096576
[No Abstract] [Full Text] [Related]
28. [Therapeutic effect of the temporary interruption of treatment of long-term parkinsonian patients: role of the peripheral metabolism of L-DOPA].
García García B; Hernández Calzadilla C; Barajas García-Talavera F; Fernández Martín F; Pérez de Paz A; Rodríguez Díaz M
Arch Neurobiol (Madr); 1986; 49(3):145-52. PubMed ID: 3741052
[No Abstract] [Full Text] [Related]
29. Low-dosage treatment in de novo patients with Parkinson's disease: a prospective study.
van der Drift JH
Adv Neurol; 1987; 45():529-34. PubMed ID: 3825731
[TBL] [Abstract][Full Text] [Related]
30. [Parlodel in early combination with levodopa in the treatment of Parkinson disease. Comparison of 2 dosage forms].
Goulley F; Wolmark Y; Bourdeix I; Chaumet-Riffaud PD
Therapie; 1993; 48(3):233-8. PubMed ID: 7908147
[TBL] [Abstract][Full Text] [Related]
31. Treatment of early morning akinesia with low-dose bromocriptine.
Lindvall B; Olsson JE
Adv Neurol; 1987; 45():543-5. PubMed ID: 3548264
[No Abstract] [Full Text] [Related]
32. Bromocriptine and lisuride in Parkinson's disease.
Caraceni T; Giovannini P; Parati E; Scigliano G; Grassi MP; Carella F
Adv Neurol; 1984; 40():531-5. PubMed ID: 6695632
[No Abstract] [Full Text] [Related]
33. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
[TBL] [Abstract][Full Text] [Related]
34. [Bromocriptine as the 1st treatment of Parkinson's disease. Long term results].
Rascol A; Montastruc JL; Guiraud-Chaumeil B; Clanet M
Rev Neurol (Paris); 1982; 138(5):401-8. PubMed ID: 7146724
[TBL] [Abstract][Full Text] [Related]
35. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
Hauser RA; Holford NH
Mov Disord; 2002 Sep; 17(5):961-8. PubMed ID: 12360545
[TBL] [Abstract][Full Text] [Related]
36. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic results with a new ergoline derivate (8-alpha-amino-ergoline, CU 32-085) in parkinsonian patients.
Schneider E; Hubener K; Fischer PA
Adv Neurol; 1984; 40():527-9. PubMed ID: 6695631
[No Abstract] [Full Text] [Related]
38. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
[TBL] [Abstract][Full Text] [Related]
39. "Long term evaluation of combined treatment of Parkinson disease with L-dopa, peripheral decarboxylase inhibitors and bromocreptine".
Caraceni T; Giovannini P; Girotti F; Parati E; Pederzoli M; Scigliano G
Ital J Neurol Sci; 1981 Dec; 2(4):337-42. PubMed ID: 7333824
[TBL] [Abstract][Full Text] [Related]
40. [Improved therapeutic response to L-dopa in Parkinson's disease, when combined with bromocriptine (author's transl)].
Ulm G
Nervenarzt; 1981 Feb; 52(2):116-20. PubMed ID: 7219619
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
